약물 용출 스텐트 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2035년)

Drug-Eluting Stents Market - Scope of Report

TMR's report on the global drug-eluting stents market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global drug-eluting stents market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global drug-eluting stents market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the drug-eluting stents market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global drug-eluting stents market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global drug-eluting stents market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global drug-eluting stents market.

The report delves into the competitive landscape of the global drug-eluting stents market. Key players operating in the global drug-eluting stents market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global drug-eluting stents market profiled in this report.

Key Questions Answered in global drug-eluting stents Market Report:

• What is the sales/revenue generated by drug-eluting stents across all regions during the forecast period?
• What are the opportunities in the global drug-eluting stents market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Drug-Eluting Stents Market - Research Objectives and Research Approach

The comprehensive report on the global drug-eluting stents market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global drug-eluting stents market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global drug-eluting stents market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Drug-Eluting Stents Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Drug-Eluting Stents Market Analysis and Forecast, 2020-2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Technological Advancements
• 5.2. PORTER's Five Forces Analysis
• 5.3. PESTEL Analysis
• 5.4. Supply Chain Analysis
• 5.5. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
• 5.6. Pricing Analysis (Brand pricing, Average Selling Price by Region/Country)
• 5.7. Regulatory Scenario by Key Country/Region
• 5.8. Research and Development Trends
• 5.9. Go-to-Market Strategy for New Market Entrants

6. Global Drug-Eluting Stents Market Analysis and Forecast, by Material

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Material, 2020-2035
  • 6.3.1. Metal
    • 6.3.1.1. Stainless-Steel
    • 6.3.1.2. Cobalt-Chromium
    • 6.3.1.3. Nitinol
    • 6.3.1.4. Others
  • 6.3.2. Polymer
    • 6.3.2.1. Non-biodegradable Polymers
    • 6.3.2.2. Biodegradable Polymers
• 6.4. Market Attractiveness Analysis, by Material

7. Global Drug-Eluting Stents Market Analysis and Forecast, by Drug

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by Drug, 2020-2035
  • 7.3.1. Sirolimus
  • 7.3.2. Paclitaxel
  • 7.3.3. Zotarolimus
  • 7.3.4. Everolimus
  • 7.3.5. Others
• 7.4. Market Attractiveness Analysis, by Drug

8. Global Drug-Eluting Stents Market Analysis and Forecast, by Application

• 8.1. Introduction & Definition
• 8.2. Key Findings/Developments
• 8.3. Market Value Forecast, by Application , 2020-2035
  • 8.3.1. Coronary Artery Disease
  • 8.3.2. Peripheral Artery Disease
  • 8.3.3. Others
• 8.4. Market Attractiveness Analysis, by Application

9. Global Drug-Eluting Stents Market Analysis and Forecast, by End-user

• 9.1. Introduction & Definition
• 9.2. Key Findings/Developments
• 9.3. Market Value Forecast, by End-user, 2020-2035
  • 9.3.1. Hospitals
  • 9.3.2. Ambulatory Surgical Centers
  • 9.3.3. Others
• 9.4. Market Attractiveness Analysis, by End-user

10. Global Drug-Eluting Stents Market Analysis and Forecast, by Region

• 10.1. Key Findings
• 10.2. Market Value Forecast, by Region, 2020-2035
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness By Region

11. North America Drug-Eluting Stents Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast, by Material, 2020-2035
  • 11.2.1. Metal
    • 11.2.1.1. Stainless-Steel
    • 11.2.1.2. Cobalt-Chromium
    • 11.2.1.3. Nitinol
    • 11.2.1.4. Others
  • 11.2.2. Polymer
    • 11.2.2.1. Non-biodegradable Polymers
    • 11.2.2.2. Biodegradable Polymers
• 11.3. Market Value Forecast, by Drug, 2020-2035
  • 11.3.1. Sirolimus
  • 11.3.2. Paclitaxel
  • 11.3.3. Zotarolimus
  • 11.3.4. Everolimus
  • 11.3.5. Others
• 11.4. Market Value Forecast, by Application , 2020-2035
  • 11.4.1. Coronary Artery Disease
  • 11.4.2. Peripheral Artery Disease
  • 11.4.3. Others
• 11.5. Market Value Forecast, by End-user, 2020-2035
  • 11.5.1. Hospitals
  • 11.5.2. Ambulatory Surgical Centers
  • 11.5.3. Others
• 11.6. Market Value Forecast, by Country, 2020-2035
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Material
  • 11.7.2. By Drug
  • 11.7.3. By Application
  • 11.7.4. By End-user
  • 11.7.5. By Country

12. Europe Drug-Eluting Stents Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast, by Material, 2020-2035
  • 12.2.1. Metal
    • 12.2.1.1. Stainless-Steel
    • 12.2.1.2. Cobalt-Chromium
    • 12.2.1.3. Nitinol
    • 12.2.1.4. Others
  • 12.2.2. Polymer
    • 12.2.2.1. Non-biodegradable Polymers
    • 12.2.2.2. Biodegradable Polymers
• 12.3. Market Value Forecast, by Drug, 2020-2035
  • 12.3.1. Sirolimus
  • 12.3.2. Paclitaxel
  • 12.3.3. Zotarolimus
  • 12.3.4. Everolimus
  • 12.3.5. Others
• 12.4. Market Value Forecast, by Application , 2020-2035
  • 12.4.1. Coronary Artery Disease
  • 12.4.2. Peripheral Artery Disease
  • 12.4.3. Others
• 12.5. Market Value Forecast, by End-user, 2020-2035
  • 12.5.1. Hospitals
  • 12.5.2. Ambulatory Surgical Centers
  • 12.5.3. Others
• 12.6. Market Value Forecast, by Country/Sub-region, 2020-2035
  • 12.6.1. Germany
  • 12.6.2. UK
  • 12.6.3. France
  • 12.6.4. Italy
  • 12.6.5. Spain
  • 12.6.6. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Material
  • 12.7.2. By Drug
  • 12.7.3. By Application
  • 12.7.4. By End-user
  • 12.7.5. By Country/Sub-region

13. Asia Pacific Drug-Eluting Stents Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast, by Material, 2020-2035
  • 13.2.1. Metal
    • 13.2.1.1. Stainless-Steel
    • 13.2.1.2. Cobalt-Chromium
    • 13.2.1.3. Nitinol
    • 13.2.1.4. Others
  • 13.2.2. Polymer
    • 13.2.2.1. Non-biodegradable Polymers
    • 13.2.2.2. Biodegradable Polymers
• 13.3. Market Value Forecast, by Drug, 2020-2035
  • 13.3.1. Sirolimus
  • 13.3.2. Paclitaxel
  • 13.3.3. Zotarolimus
  • 13.3.4. Everolimus
  • 13.3.5. Others
• 13.4. Market Value Forecast, by Application , 2020-2035
  • 13.4.1. Coronary Artery Disease
  • 13.4.2. Peripheral Artery Disease
  • 13.4.3. Others
• 13.5. Market Value Forecast, by End-user, 2020-2035
  • 13.5.1. Hospitals
  • 13.5.2. Ambulatory Surgical Centers
  • 13.5.3. Others
• 13.6. Market Value Forecast, by Country/Sub-region, 2020-2035
  • 13.6.1. China
  • 13.6.2. Japan
  • 13.6.3. India
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Material
  • 13.7.2. By Drug
  • 13.7.3. By Application
  • 13.7.4. By End-user
  • 13.7.5. By Country/Sub-region

14. Latin America Drug-Eluting Stents Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast, by Material, 2020-2035
  • 14.2.1. Metal
    • 14.2.1.1. Stainless-Steel
    • 14.2.1.2. Cobalt-Chromium
    • 14.2.1.3. Nitinol
    • 14.2.1.4. Others
  • 14.2.2. Polymer
    • 14.2.2.1. Non-biodegradable Polymers
    • 14.2.2.2. Biodegradable Polymers
• 14.3. Market Value Forecast, by Drug, 2020-2035
  • 14.3.1. Sirolimus
  • 14.3.2. Paclitaxel
  • 14.3.3. Zotarolimus
  • 14.3.4. Everolimus
  • 14.3.5. Others
• 14.4. Market Value Forecast, by Application , 2020-2035
  • 14.4.1. Coronary Artery Disease
  • 14.4.2. Peripheral Artery Disease
  • 14.4.3. Others
• 14.5. Market Value Forecast, by End-user, 2020-2035
  • 14.5.1. Hospitals
  • 14.5.2. Ambulatory Surgical Centers
  • 14.5.3. Others
• 14.6. Market Value Forecast, by Country/Sub-region, 2020-2035
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Material
  • 14.7.2. By Drug
  • 14.7.3. By Application
  • 14.7.4. By End-user
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa Drug-Eluting Stents Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast, by Material, 2020-2035
  • 15.2.1. Metal
    • 15.2.1.1. Stainless-Steel
    • 15.2.1.2. Cobalt-Chromium
    • 15.2.1.3. Nitinol
    • 15.2.1.4. Others
  • 15.2.2. Polymer
    • 15.2.2.1. Non-biodegradable Polymers
    • 15.2.2.2. Biodegradable Polymers
• 15.3. Market Value Forecast, by Drug, 2020-2035
  • 15.3.1. Sirolimus
  • 15.3.2. Paclitaxel
  • 15.3.3. Zotarolimus
  • 15.3.4. Everolimus
  • 15.3.5. Others
• 15.4. Market Value Forecast, by Application , 2020-2035
  • 15.4.1. Coronary Artery Disease
  • 15.4.2. Peripheral Artery Disease
  • 15.4.3. Others
• 15.5. Market Value Forecast, by End-user, 2020-2035
  • 15.5.1. Hospitals
  • 15.5.2. Ambulatory Surgical Centers
  • 15.5.3. Others
• 15.6. Market Value Forecast, by Country/Sub-region, 2020-2035
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Material
  • 15.7.2. By Drug
  • 15.7.3. By Application
  • 15.7.4. By End-user
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
• 16.2. Market Share Analysis, by Company (2024)
• 16.3. Company Profiles
  • 16.3.1. Abbott Laboratories
    • 16.3.1.1. Company Overview
    • 16.3.1.2. Financial Overview
    • 16.3.1.3. Product Portfolio
    • 16.3.1.4. Business Strategies
    • 16.3.1.5. Recent Developments
  • 16.3.2. AlviMedica
    • 16.3.2.1. Company Overview
    • 16.3.2.2. Financial Overview
    • 16.3.2.3. Product Portfolio
    • 16.3.2.4. Business Strategies
    • 16.3.2.5. Recent Developments
  • 16.3.3. B. Braun Melsungen AG
    • 16.3.3.1. Company Overview
    • 16.3.3.2. Financial Overview
    • 16.3.3.3. Product Portfolio
    • 16.3.3.4. Business Strategies
    • 16.3.3.5. Recent Developments
  • 16.3.4. Biosensors International Group, Ltd.
    • 16.3.4.1. Company Overview
    • 16.3.4.2. Financial Overview
    • 16.3.4.3. Product Portfolio
    • 16.3.4.4. Business Strategies
    • 16.3.4.5. Recent Developments
  • 16.3.5. Shandong JW Medical Systems LTD.
    • 16.3.5.1. Company Overview
    • 16.3.5.2. Financial Overview
    • 16.3.5.3. Product Portfolio
    • 16.3.5.4. Business Strategies
    • 16.3.5.5. Recent Developments
  • 16.3.6. Boston Scientific Corporation
    • 16.3.6.1. Company Overview
    • 16.3.6.2. Financial Overview
    • 16.3.6.3. Product Portfolio
    • 16.3.6.4. Business Strategies
    • 16.3.6.5. Recent Developments
  • 16.3.7. Cook Medical Inc.
    • 16.3.7.1. Company Overview
    • 16.3.7.2. Financial Overview
    • 16.3.7.3. Product Portfolio
    • 16.3.7.4. Business Strategies
    • 16.3.7.5. Recent Developments
  • 16.3.8. Elixir Medical Corp.
    • 16.3.8.1. Company Overview
    • 16.3.8.2. Financial Overview
    • 16.3.8.3. Product Portfolio
    • 16.3.8.4. Business Strategies
    • 16.3.8.5. Recent Developments
  • 16.3.9. Lepu Medical Technology (Beijing) Co., Ltd.
    • 16.3.9.1. Company Overview
    • 16.3.9.2. Financial Overview
    • 16.3.9.3. Product Portfolio
    • 16.3.9.4. Business Strategies
    • 16.3.9.5. Recent Developments
  • 16.3.10. Medtronic plc
    • 16.3.10.1. Company Overview
    • 16.3.10.2. Financial Overview
    • 16.3.10.3. Product Portfolio
    • 16.3.10.4. Business Strategies
    • 16.3.10.5. Recent Developments
  • 16.3.11. Eurocor GmbH
    • 16.3.11.1. Company Overview
    • 16.3.11.2. Financial Overview
    • 16.3.11.3. Product Portfolio
    • 16.3.11.4. Business Strategies
    • 16.3.11.5. Recent Developments
  • 16.3.12. OrbusNeich Medical Company Limited
    • 16.3.12.1. Company Overview
    • 16.3.12.2. Financial Overview
    • 16.3.12.3. Product Portfolio
    • 16.3.12.4. Business Strategies
    • 16.3.12.5. Recent Developments
  • 16.3.13. Shanghai MicroPort Medical Co., Ltd.
    • 16.3.13.1. Company Overview
    • 16.3.13.2. Financial Overview
    • 16.3.13.3. Product Portfolio
    • 16.3.13.4. Business Strategies
    • 16.3.13.5. Recent Developments
  • 16.3.14. Sino Medical Sciences Technology Inc.
    • 16.3.14.1. Company Overview
    • 16.3.14.2. Financial Overview
    • 16.3.14.3. Product Portfolio
    • 16.3.14.4. Business Strategies
    • 16.3.14.5. Recent Developments